Skip to content

Summit Therapeutics Sinks on FDA Rejection

The US drug regulator has declined to approve Summit's lung cancer drug ivonescimab, saying it needs proof that patients live longer. The shares fell over 16% on Monday, and the US launch date is now open.

Summit Therapeutics (NASDAQ: SMMT), the Miami-based cancer drug developer, fell about 16.5% on Monday after the FDA declined to approve its lung cancer drug ivonescimab. The company announced the decision yesterday, so Monday was the first session to trade on it.

The shares opened at $12.68, down from Friday’s close of $14.15, and finished the session around $11.82 on volume of 20.8 million shares, against typical daily turnover of 3.2 million to 7.4 million since August. That is the lowest close in data going back to the 10th of August, and the stock had already slipped from $17.84 on Monday last week.

SMMT.US

Summit said the FDA, the US drug regulator, issued a complete response letter, meaning the application cannot be approved as submitted. It covers ivonescimab plus platinum chemotherapy for lung cancer patients whose disease progressed after EGFR-targeted treatment.

According to Summit, the FDA said substantial evidence of effectiveness is not established without a statistically significant improvement in overall survival, meaning how long patients live. It said a gain in progression-free survival, the time before cancer worsens, does not support a positive benefit-risk profile on its own.

The HARMONi trial met its progression-free survival goal, but the primary overall survival analysis showed a positive trend without statistical significance. Summit points to a post-hoc analysis, run after the trial ended, with an overall survival hazard ratio of 0.76, where below 1 favours the drug. That figure is company-reported and not the primary result.

Summit Therapeutics share price drifts lower through November before dropping sharply on 16 November to the lowest close in the period shown, following the FDA's decision not to approve its lung-cancer drug.
Summit Therapeutics (SMMT.US) shares fell sharply on Monday 16 November 2026, to their lowest close since the 10th of August, the start of the period shown, after the FDA declined to approve the company’s lung-cancer drug.

Robert W. Duggan, Summit’s chairman and co-chief executive officer, said the company’s resolve is unchanged.

With five positive Phase III studies between Summit and Akeso, nothing changes with respect to our ever-growing belief in the opportunity for ivonescimab and our determination to advance ivonescimab’s development,

Robert W. Duggan, Summit Therapeutics

Akeso, the Hong Kong-listed Chinese biotech that invented ivonescimab, licenses it to Summit, and China approved it in May 2024. Summit’s other trials include HARMONi-3 and HARMONi-7 in first-line lung cancer.

The release gave no resubmission timetable for this indication. Summit’s financing includes an at-the-market equity programme and AstraZeneca made a roughly $2bn equity investment, so further share sales to fund the delay could dilute existing holders.

Asktraders News Team
Asktraders News Team
Team Member

The AskTraders Analyst Team features experts in technical and fundamental analysis, as well as traders specializing in stocks, forex, and cryptocurrency.

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.